Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Klatskin Tumor 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adrenocortical Carcinoma 1

Interventions

Cisplatin 90Fluorouracil 76Radiotherapy 63Paclitaxel 58Docetaxel 49Oxaliplatin 48Irinotecan 42Leucovorin 32Capecitabine 31Carboplatin 27Radiation 21Surgical Procedures, Operative 20Esophagectomy 20pembrolizumab 15Neoadjuvant Therapy 15Bevacizumab 15Cetuximab 13Drug Therapy 12Epirubicin 11Chemotherapy, Adjuvant 9S 1 (combination) 8Magnetic Resonance Spectroscopy 8Gemcitabine 8Trastuzumab 7Nivolumab 7Erlotinib Hydrochloride 7Surveys and Questionnaires 6Panitumumab 6Immunohistochemistry 6Chemoradiotherapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal Neoplasms × N-Ac-CHAVC-NH2 × Clear all
NCT00264433 2007-08-06

A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

Adherex Technologies, Inc.

Phase 2 Completed
EndocrineGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡